Thursday, 23 November 2017

Botanix (BOT)
Analysts | Daniel Williamson | Ian Christie, CFA

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>SPEC BUY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Price</td>
<td>5.9 cents</td>
</tr>
<tr>
<td>Valuation</td>
<td>9.5 cents</td>
</tr>
</tbody>
</table>

**Event & Impact | Positive**

The first patients have been enrolled in BOT’s Phase 1b patient study for BTX 1204, its atopic dermatitis program.

The Phase 1b study is designed to evaluate the safety and tolerability of BTX 1204 in patients with mild-to-moderate atopic dermatitis, as well as, importantly, assessing for any treatment efficacy in atopic dermatitis patients. Up to 36 patients will be enrolled for a four week treatment period across four leading dermatology clinics in Australia.

The trial is expected to be completed in Q2 CY2018, allowing a bigger Phase 2 safety and efficacy study for BTX 1204 in the US in H2 2018.

Dermatitis affects up to 25m people in the US, with current marketable treatments generating ~$3.8bn p.a. in sales. There is substantial interest in topical atopic dermatitis space, with Pfizer recently acquiring Anacor for US$5.2bn. Anacor had a topical treatment for atopic dermatitis completing Phase 3 clinical trials.

**Recommendation**

Rapid product development and a diversified pipeline de-risks BOT’s portfolio and adds value, underpinning our SPEC BUY call.
Important Disclosure
Argonaut acted as the Lead Manager to the Placement that raised $7.4M in April 2017 and will receive fees commensurate with this service. Argonaut holds or controls 12.1M BOT Options exercisable at $0.03 on or before 30 June 2019.

Information Disclosure
Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst's personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

General Disclosure and Disclaimer
This research has been prepared by Argonaut Securities Pty Limited (ABN 72 108 330 650) (“ASPL”) or by Argonaut Securities (Asia) Limited (“ASAL”) for the use of the clients of ASPL, ASAL and other related bodies corporate (the “Argonaut Group”) and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this report in any way. ASPL is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited. ASAL has a licence (AXO 052) to Deal and Advise in Securities and Advise on Corporate Finance in Hong Kong with its activities regulated by the Securities and Futures Ordinance (“SFO”) administered by the Securities and Futures Commission (“SFC”) of Hong Kong.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and ASPL and ASAL have made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Argonaut Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)’ personal views at the time of writing. No member of the Argonaut Group or its respective employees, agents or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Argonaut Group and/or its associates, including ASPL, ASAL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Argonaut Group and/or its associates, including ASPL and ASAL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the further investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on ASPL’s and/or ASAL’s overall revenues.

Hong Kong Distribution Disclosure
This material is being distributed in Hong Kong by Argonaut Securities (Asia) Limited which is licensed (AXO 052) and regulated by the Hong Kong Securities and Futures Commission. Further information on any of the securities mentioned in this material may be obtained on request, and for this purpose, persons in the Hong Kong office should be contacted at Argonaut Securities (Asia) Limited of Unit 701, 7/F, Henley Building, 5 Queen’s Road Central, Hong Kong, telephone (852) 3557 4800.

Copyright
© 2017. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Argonaut Securities Pty Limited and/or Argonaut Securities (Asia) Limited. Argonaut Securities Pty Limited and Argonaut Securities (Asia) Limited specifically prohibits the re-distribution of this document, via the Internet or otherwise, and accepts no liability whatsoever for the actions of third parties in this respect.